Artiva Biotherapeutics (NASDAQ:ARTV) Earns “Buy” Rating from HC Wainwright

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $20.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 464.97% from the stock’s previous close.

Other equities research analysts have also issued reports about the company. Cantor Fitzgerald cut their price objective on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday. Wedbush reaffirmed an “outperform” rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Tuesday. Finally, Needham & Company LLC reissued a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $20.40.

Artiva Biotherapeutics Trading Down 2.7 %

Artiva Biotherapeutics stock opened at $3.54 on Wednesday. Artiva Biotherapeutics has a 1-year low of $3.37 and a 1-year high of $17.31. The firm has a 50-day moving average of $4.78 and a 200-day moving average of $9.29.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new position in Artiva Biotherapeutics in the third quarter worth $42,000. Charles Schwab Investment Management Inc. grew its position in shares of Artiva Biotherapeutics by 8.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock worth $439,000 after buying an additional 3,233 shares during the period. Wells Fargo & Company MN increased its stake in shares of Artiva Biotherapeutics by 64.0% in the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after acquiring an additional 3,361 shares in the last quarter. Northern Trust Corp lifted its position in Artiva Biotherapeutics by 3.8% during the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock valued at $1,180,000 after acquiring an additional 4,335 shares during the period. Finally, Barclays PLC boosted its stake in Artiva Biotherapeutics by 23.2% during the fourth quarter. Barclays PLC now owns 24,161 shares of the company’s stock worth $244,000 after acquiring an additional 4,545 shares in the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.